Informing a cost-effectiveness threshold for Saudi Arabia

References

• The Embassy of The Kingdom of Saudi Arabia. Basic law of governance. 1992. Available from: https://www.saudiembassy.net/basic-law-governance.
   Google Scholar
• Kingdom of Saudi Arabia General Authority for Statistics. Population estimates. 2022. Available from: https://www.stats.gov.sa/en/43.
   Google Scholar
• Rahman R. The privatization of health care system in Saudi Arabia. Health Serv Insights. 2020;13:1178632920934497.
   Web of Science ®Google Scholar
• Al-Aqeel SA. State of health economic evaluation research in Saudi Arabia: a review. Clinicoecon Outcomes Res. 2012;4:177–184.
   PubMedGoogle Scholar
• Al-Aqeel S. Health technology assessment in Saudi Arabia. Expert Rev Pharmacoecon Outcomes Res. 2018;18(4):393–402.
   PubMed Web of Science ®Google Scholar
• Alrasheedy AA. Pharmaceutical pricing policy in Saudi Arabia: findings and implications. GaBI J. 2020;9(1):14–21.
   Google Scholar
• Al-Jazairi A, Al-Qadheeb N, Ajlan A. Pharmacoeconomic analysis in Saudi Arabia: an overdue agenda item for action. Ann Saudi Med. 2011;31(4):335–341.
   PubMed Web of Science ®Google Scholar
• GlobalData Plc. Saudi Arabia – healthcare, regulatory and reimbursement landscape; 2022. Available from: https://store.globaldata.com/report/saudi-arabia-healthcare-regulatory-and-reimbursement-analysis/.
   Google Scholar
• National Transformation Program, 2022. Available from: https://www.vision2030.gov.sa/v2030/vrps/ntp/
   Google Scholar
• Wranik WD, Székely RR, Mayer S, et al. The most important facilitators and barriers to the use of health technology assessment in Canada: a best–worst scaling approach. J Med Econ. 2021;24(1):846–856.
   PubMed Web of Science ®Google Scholar
• Dams F, Gonzalez Rodriguez JL, Cheung KL, et al. Relevance of barriers and facilitators in the use of health technology assessment in Colombia. J Med Econ. 2018;21(5):510–517.
   PubMed Web of Science ®Google Scholar
• Al Aqeel SA, Al-Sultan M. The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia: methodological recommendations. Saudi Pharm J. 2012;20(3):187–194.
   PubMed Web of Science ®Google Scholar
• Naber S, Almadi M, Guyatt G, et al. Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: the case of Saudi Arabia. Saudi J Gastroenterol. 2021;27(4):208–216.
   PubMedGoogle Scholar
• The Patented Medicine Prices Review Board. PMPRB guidelines; 2021. Available from: https://www.canada.ca/en/patented-medicine-prices-review/services/legislation/about-guidelines/guidelines.html#app-c
   Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Castilla I, et al. On the estimation of the cost-effectiveness threshold: why, what, how? Value Health. 2016;19(5):558–566.
   PubMed Web of Science ®Google Scholar
• Thokala P, Ochalek J, Leech AA, et al. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoeconomics. 2018;36(5):509–522.
   PubMed Web of Science ®Google Scholar
• Palmer S, Raftery J. Opportunity cost. BMJ. 1999;318(7197):1551–1552.
   PubMed Web of Science ®Google Scholar
• Sculpher M, Claxton K, Pearson SD. Developing a value framework: the need to reflect the opportunity costs of funding decisions. Value Health. 2017;20(2):234–239.
   PubMed Web of Science ®Google Scholar
• Padula WV, Sculpher MJ. Ideas about resourcing health care in the United States: can economic evaluation achieve meaningful use? Ann Intern Med. 2021;174(1):80–85.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. ICER 2020-2023 value assessment framework. 2020. Available from: http://www.icer-review.org/about/support/.
   Google Scholar
• Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336(7638):251–254.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Ollendorf DA. The right price: a value-based prescription for drug costs. New York: Oxford University Press; 2021.
   Google Scholar
• Alatawi AD, Niessen LW, Khan JAM. Efficiency evaluation of public hospitals in Saudi Arabia: an application of data envelopment analysis. BMJ Open. 2020;10(1):e031924.
   PubMed Web of Science ®Google Scholar
• Al-Hanawi MK, Makuta IF. Changes in productivity in healthcare services in the kingdom of Saudi Arabia. Cost Eff Resour Alloc. 2022;20(1):3.
   PubMed Web of Science ®Google Scholar
• Edney LC, Lomas J, Karnon J, et al. Empirical estimates of the marginal cost of health produced by a healthcare system: methodological considerations from country-level estimates. PharmacoEconomics. 2022;40(1):31–43.
   PubMed Web of Science ®Google Scholar
• Chi Y-L, Blecher M, Chalkidou K, et al. What next after GDP-based cost-effectiveness thresholds? Gates Open Res. 2020;4:176.
   PubMedGoogle Scholar
• The Patented Medicine Prices Review Board. Backgrounder PMPRB Draft Guidelines Consultation; 2019. Available from: https://www.canada.ca/content/dam/pmprb-cepmb/documents/consultations/draft-guidelines/backgrounder-draft-guidelines-en.pdf
   Google Scholar
• Norway Ministry of Health and Care Services. Principles for priority setting in health care – summary of a white paper on priority setting in the Norwegian health care sector; 2017. Available from: https://www.regjeringen.no/contentassets/439a420e01914a18b21f351143ccc6af/en-gb/pdfs/stm201520160034000engpdfs.pdf
   Google Scholar
• Claxton K, Martin S, Soares M, et al. Methods for the estimation of the national institute for health and care excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1–504.
   PubMed Web of Science ®Google Scholar
• van Baal P, Perry-Duxbury M, Bakx P, et al. A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Econ. 2019;28(1):87–100.
   PubMed Web of Science ®Google Scholar
• Edney LC, Haji Ali Afzali H, Cheng TC, et al. Estimating the reference incremental COST-EFFECTIVENESS ratio for the Australian health system. Pharmacoeconomics. 2018;36(2):239–252.
   PubMed Web of Science ®Google Scholar
• Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Health Policy Plan. 2020;35(5):546–555.
   PubMed Web of Science ®Google Scholar
• Ochalek J, Wang H, Gu Y, et al. Informing a cost-effectiveness threshold for health technology assessment in China: a marginal productivity approach. Pharmacoeconomics. 2020;38(12):1319–1331.
   PubMed Web of Science ®Google Scholar
• Siverskog J, Henriksson M. Estimating the marginal cost of a life year in Sweden’s public healthcare sector. Eur J Health Econ. 2019;20(5):751–762.
   PubMed Web of Science ®Google Scholar
• Stadhouders N, Koolman X, Dijk C, et al. The marginal benefits of healthcare spending in The Netherlands: estimating cost‐effectiveness thresholds using a translog production function. Health Econ. 2019;28(11):1331–1344.
   PubMed Web of Science ®Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746–761.
   PubMed Web of Science ®Google Scholar
• Espinosa O, Rodríguez-Lesmes P, Orozco L, et al. Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia. Health Policy Plan. 2022;37(3):359–368.
   PubMed Web of Science ®Google Scholar
• Moler-Zapata S, Kreif N, Ochalek J, et al. Estimating the health effects of expansions in health expenditure in Indonesia: a dynamic panel data approach. Appl Health Econ Health Policy. 2022;20(6):881–891.
   PubMed Web of Science ®Google Scholar
• Woods B, Revill P, Sculpher M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–935.
   PubMed Web of Science ®Google Scholar
• Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Glob Health. 2018;3(6):e000964.
   PubMed Web of Science ®Google Scholar
• Ochalek J, Lomas J. Reflecting the health opportunity costs of funding decisions within value frameworks: initial estimates and the need for further research. Clin Ther. 2020;42(1):44–59.e2.
   PubMed Web of Science ®Google Scholar
• Bokhari FAS, Gai Y, Gottret P. Government health expenditures and health outcomes. Health Econ. 2007;16(3):257–273.
   PubMed Web of Science ®Google Scholar
• Andrews M, Elamin O, Hall AR, et al. Inference in the presence of redundant moment conditions and the impact of government health expenditure on health outcomes in England. Econom Rev. 2017;36(1–3):23–41.
   Web of Science ®Google Scholar
• Lomas J, Martin S, Claxton K. Estimating the marginal productivity of the English National Health Service from 2003 to 2012. Value Health. 2019;22(9):995–1002.
   PubMed Web of Science ®Google Scholar
• Masterman CJ, Viscusi K. The income elasticity of global values of a statistical life: stated preference evidence. J Benefit Cost Anal. 2018;9(3):407–434.
   Web of Science ®Google Scholar
• Claxton K, Lomas J, Martin S. The impact of NHS expenditure on health outcomes in England: alternative approaches to identification in all-cause and disease specific models of mortality. Health Econ. 2018;27(6):1017–1023.
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation. Global health data exchange.|GHDx; 2022. Available from: http://ghdx.healthdata.org/.
   Google Scholar
• James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. The Lancet. 2018;392(10159):1789–1858. doi: 10.1016/S0140-6736(18)32279-7.
   PubMed Web of Science ®Google Scholar
• Saudi Arabia Ministry of Health. عن الوزارة - ميزانية الوزارة. [Internet]. Available from: https://www.moh.gov.sa/Ministry/About/Pages/Budget.aspx.
   Google Scholar
• Saudi Arabia Ministry of Finance. (للسنة الالية 1439 - 1440 هـ (2018م [Budget statement: fiscal year 2018] بيان اليزانية العامة للدولة. [Internet]; 2018. Available from: https://www.mof.gov.sa/budget/Documents/%D8%A8%D9%8A%D8%A7%D9%86%20%D8%A7%D9%84%D9%85%D9%8A%D8%B2%D8%A7%D9%86%D9%8A%D8%A9.pdf.
   Google Scholar
• Steel MFJ. Model averaging and its use in economics. J Econ Lit. 2020;58(3):644–719. doi: 10.1257/jel.20191385.
   Web of Science ®Google Scholar
• Al-Omar HA, Attuwaijri AA, Aljuffali IA. What local experts expect from a health technology assessment (HTA) entity in Saudi Arabia: workshop conclusions. Expert Rev Pharmacoecon Outcomes Res. 2020;20(1):99–104. doi: 10.1080/14737167.2019.1610398.
   PubMed Web of Science ®Google Scholar
• NICE. Guide to the methods of technology appraisal; 2013. Available from: https://www.nice.org.uk/process/pmg9/chapter/foreword.
   Google Scholar
• Kamae I, Thwaites R, Hamada A, et al. Health technology assessment in Japan: a work in progress. J Med Econ. 2020;23(4):317–322. doi: 10.1080/13696998.2020.1716775.
   PubMed Web of Science ®Google Scholar
• Department of Health Philippines. Philippine HTA methods guide; 2020. Available from: https://hta.doh.gov.ph/philippine-hta-process-guide/.
   Google Scholar
• Robberstad B. QALYs vs DALYs vs LYs gained: what are the differences, and what difference do they make for health care priority setting? Nor J Epidemiol. 2009;15(2):183–191. doi: 10.5324/nje.v15i2.217.
   Google Scholar
• Neumann PJ, Anderson JE, Panzer AD, et al. Comparing the cost- per-QALYs gained and cost-per-DALYs averted literatures. Gates Open Res. 2018;2:5. doi: 10.12688/gatesopenres.12786.1.
   PubMedGoogle Scholar
• Paulden M, McCabe C. Modifying NICE’s approach to equity weighting. Pharmacoeconomics. 2021;39(2):147–160. doi: 10.1007/s40273-020-00988-2.
   PubMed Web of Science ®Google Scholar
• Vanness DJ, Lomas J, Ahn H. A health opportunity cost threshold for cost-effectiveness analysis in the United States. Ann Intern Med. 2021;174(1):25–32. doi: 10.7326/M20-1392.
   PubMed Web of Science ®Google Scholar
• Pandey H, Paulden M, McCabe C. Theoretical models of the cost- effectiveness threshold, value assessment, and health care system sustainability; 2018.
   Google Scholar
• Kourouklis D, Sampson C, Berdud M, et al. Building cost-effectiveness thresholds for the future. Value Outcomes Spot. 2022;8(4):30–33.
   Google Scholar
• Woods B, Lomas J, Sculpher M, et al. Achieving dynamic efficiency in pharmaceutical innovation: identifying the optimal share of value, the payments required and evaluating pricing policies; 2022. Available from: https://eepru.sites.sheffield.ac.uk/ reports-publications./reports.
   Google Scholar
• Claxton K, Asaria M, Chansa C, et al. Accounting for timing when assessing health-related policies. J Benefit Cost Anal. 2019;10(Suppl 1):73–105. doi: 10.1017/bca.2018.29.
   PubMedGoogle Scholar
• Paulden M, O'Mahony J, McCabe C. Determinants of change in the cost-effectiveness threshold. Med Decis Making. 2017;37(2):264–276. doi: 10.1177/0272989X16662242.
   PubMed Web of Science ®Google Scholar
• Bazarbashi S, De Vol EB, Maraiki F, et al. Empirical monetary valuation of a quality-adjusted life-year in the kingdom of Saudi Arabia: a willingness-to-pay analysis. Pharmacoecon Open. 2020;4(4):625–633. doi: 10.1007/s41669-020-00211-0.
   PubMed Web of Science ®Google Scholar
• Brouwer W, van Baal P, van Exel J, et al. When is it too expensive? Cost-effectiveness thresholds and health care decision-making. Eur J Health Econ. 2019;20(2):175–180. doi: 10.1007/s10198-018-1000-4.
   PubMed Web of Science ®Google Scholar
• Gloria MAJ, Thavorncharoensap M, Chaikledkaew U, et al. A systematic review of demand-side methods of estimating the societal monetary value of health gain. Value Health. 2021;24(10):1423–1434. doi: 10.1016/j.jval.2021.05.018.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Phelps CE. Health technology assessment with risk aversion in health. J Health Econ. 2020;78:102474. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0167629619309208
   Web of Science ®Google Scholar
• DHSC. Voluntary scheme for branded medicines pricing and access: heads of agreement; 2018. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/807856/CEMIPP_Consultation_Response_1.pdf.
   Google Scholar
• DHSC. Cost-effectiveness methodology for immunisation programmes and procurements (CEMIPP) The government’s decision and summary of consultation responses; 2019. Available from: https://www.gov.uk/government/publications/voluntary-scheme-for-branded-medicines-pricing-and-access-heads-of-agreement/voluntary-scheme-for-branded-medicines-pricing-and-access-heads-of-agreement.
   Google Scholar
• PMLiVE. NICE unveils long-awaited review of methodologies; 2019. Available from: https://www.pmlive.com/pharma_news/nice_unveils_long-awaited_review_of_methodologies_1295100.
   Google Scholar
• PMPRB. Backgrounder on June 2020 draft guidelines: explanation of changes from November 2019 draft guidelines; 2020. Available from: https://www.canada.ca/content/dam/pmprb-cepmb/documents/consultations/draft-guidelines/2020/PMPRB-Backgrounder 2020-en.pdf.
   Google Scholar